Results 81 to 90 of about 696 (142)

Hot topics in allergen immunotherapy, 2023: Current status and future perspective

open access: yesAllergy, Volume 79, Issue 4, Page 823-842, April 2024.
Abstract The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality‐of‐life improvements and cost‐effectiveness in the long term. Key mechanisms of allergen tolerance induced by AIT include changes in memory type allergen‐specific T‐ and B‐cell responses towards a regulatory phenotype with decreased Type 2 ...
Magdalena Zemelka‐Wiacek   +11 more
wiley   +1 more source

Epicutaneous immunization with ovalbumin and CpG induces TH1/TH17 cytokines, which regulate IgE and IgG2a production [PDF]

open access: yes, 2016
Background: Subcutaneous allergen-specific immunotherapy is a standard route for the immunotherapy of allergic diseases. It modulates the course of allergy and can generate long-term remission.
Askenase, Philip William   +5 more
core   +1 more source

Phase 1 trial supports safety and mechanism of action of peptide immunotherapy for peanut allergy

open access: yesAllergy, Volume 79, Issue 2, Page 485-498, February 2024.
PVX108 is a peptide immunotherapy designed to treat peanut allergy. PVX108 induced negligible activation of peanut‐sensitized basophils ex vivo. A randomized, placebo‐controlled Phase 1 clinical trial showed that PVX108 was safe and well tolerated in peanut‐allergic adults and induced a shift in peanut‐reactive T‐cell phenotype balance to reduce Th2A ...
Astrid L. Voskamp   +16 more
wiley   +1 more source

Associations between gender and health‐related quality of life in people with IgE‐mediated food allergy and their caregivers: A systematic review

open access: yesClinical &Experimental Allergy, Volume 54, Issue 2, Page 93-108, February 2024.
We systematically reviewed the impact of gender on health‐related quality of life (HRQL) in populations with immunoglobulin‐E‐mediated food allergy. Females with food allergy self‐report poorer baseline HRQL than males, regardless of age. Gender may impact total HRQL and subdomain HRQL in food allergy studies.
Sophie A. Rosser   +4 more
wiley   +1 more source

Current trends in peanut allergy immunotherapy: a review

open access: yesAlergologia Polska
Peanut allergy (PA) poses significant clinical challenges due to its potentially life-threatening nature and increasing prevalence, particularly in children.
Klementyna Łyżwa   +4 more
doaj   +1 more source

State of the Art on Food Allergy Immunotherapy [PDF]

open access: yes, 2020
Food allergy is increasing in prevalence in westernized countries, leading to significant morbidity including nutritional deficiencies and the potential for fatal anaphylaxis during accidental exposure to the allergen.
Docena, Guillermo Horacio   +1 more
core  

An algorithm for the diagnosis and management of IgE‐mediated food allergy, 2024 update

open access: yes
Allergy, Volume 80, Issue 2, Page 629-632, February 2025.
Alexandra F. Santos   +3 more
wiley   +1 more source

Új, epicutan módszer az allergia oki kezelésére | New – epicutaneous – method for the causal treatment of allergic diseases [PDF]

open access: yes, 2017
Absztrakt: Az allergénspecifikus immunkezelés az allergia egyetlen oki kezelése. Injekciós és per os formái mellett legújabban epicutan módszer is ismert.
Endre, László
core   +1 more source

A practical view of immunotherapy for food allergy [PDF]

open access: yes, 2016
Food allergy is common and sometimes life threatening for Korean children. The current standard treatment of allergen avoidance and self-injectable epinephrine does not change the natural course of food allergy.
Tae Won Song
core   +1 more source

Food allergies: Current and future treatments [PDF]

open access: yes, 2019
Food allergies are an increasingly public health problem, affecting up to 10% of children and causing a significant burden on affected patients, resulting in dietary restrictions, fear of accidental ingestion and related risk of severe reactions, as well
Brambilla I.   +7 more
core   +1 more source

Home - About - Disclaimer - Privacy